The estimated Net Worth of Warren Jr Nighan is at least $1.55 Milión dollars as of 17 July 2024. Mr Nighan owns over 5,677 units of Angiodynamic Inc stock worth over $346,329 and over the last 14 years he sold ANGO stock worth over $580,946. In addition, he makes $622,112 as Sr. VP of Quality & Regulatory Affairs at Angiodynamic Inc.
Mr has made over 4 trades of the Angiodynamic Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he exercised 5,677 units of ANGO stock worth $42,123 on 17 July 2024.
The largest trade he's ever made was selling 8,258 units of Angiodynamic Inc stock on 11 December 2012 worth over $332,054. On average, Mr trades about 1,477 units every 318 days since 2011. As of 17 July 2024 he still owns at least 46,675 units of Angiodynamic Inc stock.
You can see the complete history of Mr Nighan stock trades at the bottom of the page.
Warren G. Nighan is the Sr. VP of Quality & Regulatory Affairs at Angiodynamic Inc.
As the Sr. VP of Quality & Regulatory Affairs of Angiodynamic Inc, the total compensation of Mr Nighan at Angiodynamic Inc is $622,112. There are 9 executives at Angiodynamic Inc getting paid more, with James Clemmer having the highest compensation of $3,116,630.
Mr Nighan is 52, he's been the Sr. VP of Quality & Regulatory Affairs of Angiodynamic Inc since . There are 18 older and 8 younger executives at Angiodynamic Inc. The oldest executive at Angiodynamic Inc is Dennis Meteny, 67, who is the Independent Director.
Warren's mailing address filed with the SEC is 14 PLAZA DRIVE, , LATHAM, NY, 12110.
Over the last 21 years, insiders at Angiodynamic Inc have traded over $207,843,757 worth of Angiodynamic Inc stock and bought 255,612 units worth $3,086,102 . The most active insiders traders include David F Burgstahler, Sriram Venkataraman a Capital Partners Gp, Llc Av.... On average, Angiodynamic Inc executives and independent directors trade stock every 36 days with the average trade being worth of $826,492. The most recent stock trade was executed by Laura Piccinini on 17 July 2024, trading 4,439 units of ANGO stock currently worth $32,937.
founded in 1988 in queensbury, n.y., u.s., angiodynamics is today a nasdaq-listed public company. we are a leading provider of innovative medical devices used by interventional radiologists, nephrologists and surgeons for the minimally invasive treatment of cancer and peripheral vascular disease. our diverse product line includes market-leading radiofrequency ablation and nanoknife® systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. angiodynamics has distinguished itself as a dynamic brand in a technologically competitive, high-growth industry, through the company’s consistent ability to successfully develop and bring to market new technologies and products. angiodynamics believes it is well poised to continue that trend. looking into the future, the company plans to bring forth a continuing stream of innovations that greatly improve patie
Angiodynamic Inc executives and other stock owners filed with the SEC include: